Dysgeusia News and Research

RSS
FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Hedgehog blockade promising in myeloid malignancies

Hedgehog blockade promising in myeloid malignancies

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

European Commission amends marketing authorisation for Celgene's REVLIMID

European Commission amends marketing authorisation for Celgene's REVLIMID

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

GE Healthcare seeks approval to supply Optison to EU market from Oslo manufacturing facility

GE Healthcare seeks approval to supply Optison to EU market from Oslo manufacturing facility

Study projects potential impact of FDA-approved anti-obesity medications on Medicare spending

Study projects potential impact of FDA-approved anti-obesity medications on Medicare spending

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer